# Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

> **NCT06506955** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Taiho Oncology, Inc.** · enrollment: 15 (estimated)

## Conditions studied

- Advanced/Metastatic Cancer

## Interventions

- **DRUG:** futibatinib
- **DRUG:** futibatinib, fulvestrant

## Key facts

- **NCT ID:** NCT06506955
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-10-01
- **Primary completion:** 2027-04
- **Final completion:** 2027-04-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06506955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06506955, "Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06506955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*